Pharmafile Logo
Pharmafocus logo
Advanced Search

ChemoCentryx

Showing 2 posts of 2 posts found.

GSK moves Crohn’s disease drug into phase III

January 14, 2011
Research and Development ChemoCentryx, Crohn’s disease, GSK’786, GlaxoSmithKline, Traficet-EN

GlaxoSmithKline and its partner ChemoCentryx have started late-stage trials of GSK’786 for Crohn’s disease. The initial study is a randomised, …

News

Signs of product payoff from GSK’s $1.5bn alliance

January 12, 2010
Research and Development ChemoCentryx, Crohn's, GlaxoSmithKline

GlaxoSmithKline is to develop and commercialise a drug which hopes will be a treatment for moderate-to-severe Crohn’s disease. Californian biotech …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025